雷珠单抗(Ranibizumab (Genentech)) - 药物靶点：VEGF-A_在研适应症：早产儿视网膜病变，糖尿病性视网膜病变，年龄相关性黄斑变性_专利_临床

概要

基本信息

药物类型

Fab片段抗体

别名

ACCENTRIX、AMD Fab、AMD-FAB

+ [17]

靶点

VEGF-A

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [3]

在研适应症

早产儿视网膜病变糖尿病性视网膜病变年龄相关性黄斑变性+ [6]

非在研适应症

水疱缺血型视网膜中央静脉阻塞抑郁症+ [26]

原研机构

Genentech, Inc.

在研机构

Hoffmann-La Roche, Inc.

Genentech, Inc.Novartis Europharm Ltd.

+ [7]

非在研机构

Novartis Pharmaceuticals Corp.

北京诺华制药有限公司Novartis Pharma Stein AG

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2006-06-30),

湿性年龄相关性黄斑变性

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (澳大利亚)

登录后查看时间轴

序列信息

Sequence Code 103170L

来源: *****

Sequence Code 143622H

来源: *****

关联

389

项与雷珠单抗相关的临床试验

NCT05562947 / Recruiting临床3期

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

开始日期2024-06-17

申办/合作机构

Hoffmann-La Roche, Inc.

TCTR20240924004 / CompletedN/AIIT

Evaluation of Sterility, Stability, and Efficacy of Repackaged Bevacizumab, Aflibercept, Ranibizumab, Brolucizumab, and Faricimab for Intravitreal Administration: An Experimental Study

开始日期2024-04-10

申办/合作机构-

CTR20222633 / Recruiting临床3期

一项在中国新生血管性年龄相关性黄斑变性患者中评估雷珠单抗眼内港式给药系统的有效性、安全性和药代动力学特征的III 期、多中心、随机、视力评估员设盲、阳性对照研究

本研究将在中国nAMD患者中评估与雷珠单抗0.5 mg Q4W玻璃体内注射相比，雷珠单抗100 mg/mL通过眼内港式给药系统植入Q24W给药的有效性、安全性和药代动力学特征。

开始日期2024-04-02

申办/合作机构

F. Hoffmann-La Roche Ltd.

[+2]

100 项与雷珠单抗相关的临床结果

登录后查看更多信息

100 项与雷珠单抗相关的转化医学

登录后查看更多信息

100 项与雷珠单抗相关的专利（医药）

登录后查看更多信息

5,119

项与雷珠单抗相关的文献（医药）

2025-01-01·JOURNAL FRANCAIS D OPHTALMOLOGIE

Ranibizumab treatment improves the reading speed of patients with neovascular age-related macular degeneration: A nonrandomized clinical trial using the Radner reading chart

Article

作者: Csutak, A ; Hayek, G ; Perone, J.-M. ; Goetz, C ; Perone, J-M ; Reglodi, D ; Hayek, G. ; Csutak, A. ; Reglodi, D. ; Goetz, C.

PURPOSE:

Intravitreal injections with anti-vascular endothelial growth factor (VEGF) drugs can slow progression in neovascular age-related macular degeneration (nAMD). Best spectacle-corrected visual acuity (BSCVA) and/or central retinal thickness (CRT) are common barometers of efficacy of this treatment. However, BSCVA does not accurately measure reading ability, which is often severely impacted by nAMD. Since most studies on the effect of intravitreal anti-VEGF injections on reading ability in nAMD have limitations, we conducted an open-label nonrandomized non-blinded self-controlled clinical trial using Radner Charts, a standardized, validated tool for measuring reading ability.

METHODS:

Patients newly diagnosed with active nAMD and scheduled to undergo induction ranibizumab treatment (monthly treatments for 3months) were recruited by convenience sampling in 2010-2013 at a university hospital. The primary outcome was change in Radner Chart-determined reading speed (maximum words/minute [wpm]) at 3months (1month post-third injection) relative to baseline. Secondary outcome measures were 3-month change in BSCVA and CRT. Treatment-induced effects on wpm, BSCVA, and CRT were determined with Wilcoxon tests. Spearman correlations between these variables were evaluated.

RESULTS:

The injections significantly improved wpm (48 to 75), BSCVA (+9 letters), and CRT (357 to 224μm) (all P<0.0001). BSCVA, but not CRT, correlated with wpm at baseline and 3months (P=0.0004 and 0.03, respectively). BSCVA and CRT were not correlated, unless change in these variables was considered, possibly because of a non-linear relationship.

CONCLUSION:

Anti-VEGF treatment significantly improved reading ability. Whether BSCVA can serve as a clinically meaningful assessment of reading ability requires further research. Baseline variables may not help to identify patients with poor reading speed responses to treatment.

2025-01-01·ARQUIVOS BRASILEIROS DE OFTALMOLOGIA

Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?

Article

作者: Akbas, Yusuf Berk ; Ozkaya, Abdullah ; Demir, Gokhan ; Çakmak, Semih ; Artunay, Ozgur ; Sukun, Elmas Yuksel ; Tunç, Uğur ; Erdogan, Gurkan

PURPOSE:

To compare the outcomes of intravitreal dexamethasone implant used as either an adjuvant or a switching therapy for diabetic macular edema in patients with poor anatomic response after three consecutive monthly injections of ranibizumab.

METHODS:

This retrospective study included patients with diabetic macular edema who received three consecutive doses of ranibizumab as initial therapy and demonstrated poor response. A single dose of intravitreal de xamethasone implant was administered to these patients. The patients were divided into two groups according to the treatment modalities: the adjuvant therapy group, consisting of patients who continued treatment with ranibizumab injection after receiving intravitreal dexamethasone implant, and the switch therapy group, consisting of patients who were switched from ranibizumab treatment to intravitreal dexamethasone implant as needed. The main outcome measurements were best corrected visual acuity and central retinal thickness at baseline and at 3, 6, 9, and 12 months of follow-up.

RESULTS:

In this study that included 64 eyes of 64 patients, the best corrected visual acuity and central retinal thickness values did not significantly differ between the groups at baseline and at 6 months of follow-up (p>0.05). However, at 12 months, the best corrected visual acuity values in the adjuvant and switch therapy groups were 0.46 and 0.35 LogMAR, respectively (p=0.012), and the central retinal thickness values were 344.8 and 270.9, respectively (p=0.007).

CONCLUSIONS:

In a real-world setting, it seems more reasonable to use intravitreal dexamethasone implant as a switch therapy rather than an adjuvant therapy for diabetic macula edema refractory to ranibizumab despite three consecutive monthly injections of ranibizumab. Patients switched to intravitreal dexamethasone implant were found to have better anatomic and visual outcomes at 12 months than those who continued ranibizumab therapy despite their less-than-optimal responses.

2024-12-01·Photodiagnosis and Photodynamic Therapy

Comparison of visual acuity outcome and choroidal thickness variation of intravitreal ranibizumab injection for myopic choroidal neovascularization with or without dome-shaped macula

Article

作者: Yin, Xiao-Fang ; Liang, Chen ; Lu, Yan ; Wu, Min-Hui ; Ye, Zu-Ke ; Luo, Yu-Ting ; Guo, Xiu-Juan

BACKGROUND:

To investigate the visual acuity outcome and choroid thickness (CT) change after intravitreal ranibizumab in highly myopic eyes with or without dome-shaped macula (DSM) in Chinese patients.

METHODS:

This retrospective, observative study included 80 treatment-naive eyes (80 patients), which received ranibizumab according to the 1+PRN protocol. The best corrective visual acuity (BCVA) and CT change were compared between eyes with or without DSM.

RESULTS:

There was no significant difference between eyes with or without DSM in BCVA and central macular thickness (CMT). The recurrent rate was not different between the two groups during the first year of treatment. The CT was significantly thinner in eyes with DSM than in eyes without DSM before treatment (median 40.00um versus 71.00um), at 1 month after treatment (median 31.00um versus 65.50um), and in the last follow up (median, 32.00um versus 65.00um) (p = 0.0101). Axial length (AL) was longer in eyes with DSM than those without DSM (median, 29.17 mm versus 28.10 mm) before treatment, and in the last follow up (median, 29.44 mm versus 28.20 mm) (p = 0.0055). The CT was significantly correlated with AL (p < 0.0001).

CONCLUSIONS:

No difference was found in visual outcome between eyes with or without DSM. The visual acuity significantly improved at 1 month after ranibizumab injection and it was recovery sooner in extrafoveal choroidal neovascularization (CNV) group than in subfoveal CNV group. The CT was thinner in eyes with DSM, which was significantly correlated with AL.

619

项与雷珠单抗相关的新闻（医药）

2024-11-12

·GlobeNewswire-Health Care

Opthea’s Wet AMD Program Featured at Ophthalmology Events

17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences. Conference details are as follows: The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS) Session: Rapid Fire 4 – Retina (Medical & Surgical)Timing: Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8)Presentation: Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup AnalysisPresenter: Gregg T. Kokame, MD, MMM, FASRSAbstract: https://2024.apvrs.org/abstract/?code=200963 Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone. APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovationsand therapies, and latest advances in imaging and research. Ophthalmology Innovation Summit XIV (OIS) Session: Retina Innovation ShowcaseTiming: Saturday, November 23, 2024, 11:15 AM – 12:50 PM PTPresenter: Frederic Guerard, PharmD, CEO, OptheaAgenda: https://ois.net/ois-xiv-agenda/ The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate. About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Authorized for release to ASX by Frederic Guerard, PharmD, CEO Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited

临床2期临床3期临床结果

2024-11-12

·齐鲁制药集团

AI唤醒旧时光，原来激情岁月可回头！

泛黄的相纸斑驳的影像是过往岁月的低语更是时光深处的呢喃连接着过去与现在让企业成长的脉络在眼前缓缓铺展用AI技术让记忆焕发新生穿越时光的迷雾触摸那些逝去的日子重温前辈的创业历程感受他们的热血奋斗传承他们的创新精神在未来的时光里绽放属于自己的光芒砖瓦小楼里一项项大政方针酝酿成熟一个个产品项目悄然萌芽希望的灯火在不起眼的角落持续闪耀照亮了那两片略显沧桑的旧厂房就在这里大伙儿不分昼夜与时间赛跑不顾烈日炎炎风雨交加用人力扛起沉重的机器设备用坚毅书写着拼搏的篇章戳下方图片 AI 动起来最早的质量实验室里一台二手老式瓦瑞安液相色谱仪与数架古朴的机械天平并肩而立十几位心怀热忱的检测人员以汗水为墨以实干为笔在齐鲁产品的品质画卷上细细勾勒层层加固筑起一道坚不可摧的质量防线精心擦亮齐鲁产品的金字招牌戳下方图片 AI 动起来沧桑老厂房诉说着岁月艰辛见证了齐鲁儿女的坚韧不拔他们远赴全国各地学习先进生产技术无数个日夜潜心钻研在工艺的迷雾中不懈探索在操作的细节中反复推敲狭小的生存空间里他们以智慧为刃攻克重重难关将一瓶瓶承载着健康希望的药品送达全国每一个角落戳下方图片 AI 动起来从模仿大厂起步亲手打造简陋的设备没有大型机械辅助他们凭借双手与肩膀的力量一步步将希望的种子深植让设备稳稳落地他们以不屈不挠的精神在挑战中坚韧前行以坚持不懈的努力为生产铺就坚实的硬件基石戳下方图片 AI 动起来于狭缝中顽强生存在困境里奋力突围老一辈齐鲁人用沸腾热血与璀璨青春奏响一曲曲激昂的生命乐章这不仅是对往昔的温情回望更是梦想与坚持交织的壮丽篇章每一次跨越的尝试都是对健康的深情倾注每一步不懈的奋斗都闪耀着勇敢与坚韧的光芒戳下方图片 AI 动起来如今拼搏、实干、创新、奉献的齐鲁精神在岁月长河里历久弥新它们必将持续引领企业不断前行奔向高远跑赢未来书写属于齐鲁更辉煌的篇章策划、编辑：白子健、王彩云点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

2024-11-11

·齐鲁制药集团

齐鲁制药抗肿瘤创新药QLP2117一期临床研究数据在2024年SITC年会发布

11月6-10日，第39届癌症免疫治疗学会（SITC）年会在美国休斯顿召开，齐鲁制药QLP2117注射液用于治疗晚期实体瘤患者的1a期临床试验最新数据以壁报形式发布。 C-C基序趋化因子受体8（C-C motif chemokine receptor 8，CCR8）是肿瘤微环境中调节性T细胞（Tregs）上表达的一种重要的趋化因子受体。通过靶向CCR8选择性地清除肿瘤内调节性Treg有望成为一种很有前景的治疗策略。QLP2117是一种靶向CCR8 的高选择性IgG1抗体，通过去岩藻糖基化工程增强了抗体依赖的细胞介导的细胞毒作用（ADCC）。此外，它还能介导NK细胞直接杀伤Tregs，通过抑制Tregs的活性来解除免疫抑制，阻断CCR8与其配体CCL1的结合，并抑制Tregs的招募。本研究的主要研究者为中山大学肿瘤防治中心的徐瑞华教授。本研究招募晚期实体瘤患者，采用加速滴定设计和BOIN研究设计进行QLP2117输注给药，主要研究目的为安全性、耐受性和初步疗效。至数据截止，研究仍在进行中。截至9月9日，研究共纳入18例受试者，其中3mg、10mg、30mg剂量组各1例，90mg剂量组3例，270mg和540mg剂量组各6例。QLP2117的安全性可控。有1例受试者达到部分缓解（PR）。截至9月9日，1例受试者持续13个月疾病稳定（SD）。所有受试者在接受QLP2117治疗后Treg II均显示降低。一例鼻咽癌受试者的活检结果表明，在接受了3个周期的QLP2117治疗后，CCR8表达水平下降。外周Treg细胞耗竭综上，QLP2117在实体瘤患者中的安全性和耐受性良好，并显示出初步的疗效，基于QLP2117的联合治疗方案值得进一步探索。撰稿：李凌艳、张美江、吴苏嘉点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

抗体药物偶联物临床1期

100 项与雷珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05697	雷珠单抗	S01LA04	DB01270

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
早产儿视网膜病变	日本	Novartis Pharma KK	2019-11-22
糖尿病性视网膜病变	美国	Genentech, Inc.	2015-02-06
年龄相关性黄斑变性	日本	Novartis Pharma AG	2009-01-21
脉络膜新生血管	欧盟	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	冰岛	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	列支敦士登	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	挪威	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	欧盟	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	冰岛	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	列支敦士登	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	挪威	Novartis Europharm Ltd.	2007-01-22
视觉障碍	欧盟	Novartis Europharm Ltd.	2007-01-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
近视	临床3期	中国	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	中国香港	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	印度	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	菲律宾	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	韩国	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	泰国	Novartis Pharmaceuticals Corp.	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Europharm Ltd.	2013-09-11
近视脉络膜新生血管	临床3期	中国	北京诺华制药有限公司	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Pharma Stein AG	2013-09-11
近视脉络膜新生血管	临床3期	印度	Novartis Europharm Ltd.	2013-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	Intravitreal Ranibizumab (IVR)	襯衊襯繭築糧壓積網網(艱鹹齋餘壓窪鹹顧獵糧) = 餘壓鬱廠膚鹽範鏇製廠願醖構齋餘簾衊願構餘 (選範鹽膚廠願鏇願網鏇 ) 更多	-	2024-09-19
				Intravitreal Aflibercept (IVA)	襯衊襯繭築糧壓積網網(艱鹹齋餘壓窪鹹顧獵糧) = 衊夢壓憲壓膚鹽鏇簾夢願醖構齋餘簾衊願構餘 (選範鹽膚廠願鏇願網鏇 ) 更多
EURETINA2024	N/A	-	-	Intravitreal Ranibizumab	膚簾網齋鏇網憲簾選製(範衊膚鏇鑰鹽廠觸淵餘) = 衊憲構網齋繭願齋選選膚鏇廠窪膚願夢窪艱艱 (觸憲鹽蓋網壓鏇觸淵鹹 )	-	2024-09-19
				Ranibizumab (Laser photocoagulation)	膚簾網齋鏇網憲簾選製(範衊膚鏇鑰鹽廠觸淵餘) = 網築簾廠鬱鑰鏇憲淵鏇膚鏇廠窪膚願夢窪艱艱 (觸憲鹽蓋網壓鏇觸淵鹹 )
EURETINA2024	N/A	玻璃体积血	-	Intravitreal Ranibizumab	網艱膚獵鏇蓋構構簾餘(糧淵齋膚網鬱壓艱繭鏇) = 簾鹽餘夢製齋鹽願夢選廠糧製廠淵鏇窪繭鬱餘 (壓齋廠簾顧願製築衊鬱 ) 更多	-	2024-09-19
Archway, Portal, Ladder (EURETINA2024)	临床2/3期	湿性年龄相关性黄斑变性 vascular endothelial growth factor	-	Port Delivery System with ranibizumab (PDS)	糧醖艱鏇壓鬱淵顧齋築(壓窪醖鹽範餘遞繭繭鏇) = BCVA remained stable for 5 years, with an observed BCVA Snellen equivalent of 20/40 and mean (95% CI) change from baseline of −1.8 ETDRS letters (−8.1, 4.4; n=17) at month 60 構膚壓構衊襯鏇襯廠觸 (鏇積襯繭廠膚構淵獵構 ) 更多	积极	2024-09-19
				Monthly intravitreal ranibizumab injections
EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	PDS with ranibizumab 100 mg/mL with fixed 24-week refill-exchanges (Q24W)	齋觸簾觸窪繭壓願願壓(蓋鑰構網衊膚鏇壓廠淵) = 範鬱壓夢繭鏇鑰鏇淵製襯積衊構構網襯醖觸願 (壓壓淵積淵鑰鹹遞網蓋 )	-	2024-09-19
				Intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab)	齋觸簾觸窪繭壓願願壓(蓋鑰構網衊膚鏇壓廠淵) = 網積鬱顧鬱膚襯夢鬱衊襯積衊構構網襯醖觸願 (壓壓淵積淵鑰鹹遞網蓋 )
EURETINA2024	N/A	早产儿视网膜病变	131	Intravitreal injection of Ranibizumab 0.25 mg/0.025 ml	廠簾鹹選選憲築鹹齋憲(艱繭積襯製顧鏇膚壓選) = 遞餘鑰艱餘廠醖範獵顧醖壓艱壓襯醖觸簾顧網 (艱廠構憲積網壓構鬱淵, 1.37) 更多	积极	2024-09-19
EURETINA2024	N/A	糖尿病性黄斑水肿	-	Ranibizumab (PDS Q24W)	鏇顧獵願糧鹽簾襯齋鏇(積襯願齋築壓壓範糧顧) = 膚鏇衊簾鬱醖膚壓醖鬱製糧壓糧糧襯憲構鏇構 (簾範願糧繭襯鑰糧醖遞, 8.7 ~ 1.5) 更多	-	2024-09-19
				Monthly ranibizumab	鏇顧獵願糧鹽簾襯齋鏇(積襯願齋築壓壓範糧顧) = 憲淵顧製壓獵蓋膚夢艱製糧壓糧糧襯憲構鏇構 (簾範願糧繭襯鑰糧醖遞, 8.3 ~ 10.5) 更多
EURETINA2024	N/A	糖尿病性视网膜病变	-	Port Delivery System with ranibizumab Q36W	獵艱積衊遞膚觸醖製壓(糧鬱網蓋遞醖窪糧願糧) = No events of device dislocation were reported in either arm through W100 餘範鹽鏇廠窪遞遞餘夢 (憲窪糧艱範選鹹選醖壓 ) 更多	-	2024-09-19
				Ranibizumab (Control arm)
NCT02510794 \| NCT03683251 \| NCT03677934 (Pubmed \| Ophthalmol Retina)	临床2/3期	眼内炎	555	Port Delivery System with ranibizumab (PDS)	襯糧範網簾範獵築鹹獵(齋廠襯窪鬱鹽範網淵蓋) = Twelve endophthalmitis events were reported in 11 patients (11/555 [2.0%]) through March 12, 2021. All were cultured (3 were culture positive) and treated with intravitreal antibiotics. Two cases (2/555 [0.4%]) occurred in the immediate postoperative period (days 5 and 6). Nine cases occurred later (day range: 57-853), including 4 before the first refill-exchange (day range: 57-161). Five patients received between 1-11 refill-exchanges before the event (onset: 6-168 days after last refill-exchange). Seven cases (7/11 [63.6%]) had preceding/concurrent conjunctival complications. At last follow-up, 7 patients recovered vision to study baseline levels or ≥ 20/40; 4 patients experienced vision loss of ≥ 15 ETDRS letters. 鑰觸顧築鏇蓋鹽鬱網構 (觸鑰網夢壓獵網艱簾獵 ) 更多	积极	2024-08-16
NCT04108156 (Pavilion, NEWS) 人工标引	N/A	糖尿病性黄斑水肿 \| 糖尿病性视网膜病变	-	Susvimo	鏇範獵襯艱齋艱觸積蓋(構衊淵夢襯築餘築積憲) = 餘鹹窪鹹餘鏇襯範顧鏇網鏇鏇鹹築獵餘廠襯淵 (窪鹽選網壓餘鏇積繭廠 )	积极	2024-07-18